Pharmaceutical and Health Tech companies join efforts to provide pain care prescribers with regulatory compliance-based risk mitigation tools to improve patient care
Innovative specialty pharmaceutical company, Protega Pharmaceuticals Inc., announced that it has signed an exclusive agreement with OPOS, Inc., in which they are aligning efforts to reduce opioid prescriber and patient risks through comprehensive, personalized technology-enabled services and education.
OPOS delivers technology-enabled solutions for opioid regulatory compliance and optimization, integrating advanced AI predictive analytics, patient education, and medication monitoring through an extensive SaaS platform to support physician practices nationwide. The solutions enable providers who prescribe long-term opioid therapy as part of a multimodal treatment plan to educate patients and compliantly aid in managing patients’ chronic pain.
Health Technology Insights: Advantia Health Teams Up with Mirvie for Predictive Maternal Care
According to a Centers for Disease Control and Prevention (CDC) report, in 2023, 24.3% of U.S. adults experienced chronic pain in the previous three months, highlighting the critical need for advanced pain management solutions.
“This collaboration supports our mission to improve patient care and reduce risks involved with pain management, as OPOS is dedicated to improving access to well-rounded total pain care and aiding providers in maintaining regulatory compliance while prescribing the lowest effective amount of opioid medication to optimize patient care,” said Paul Howe, Chief Operations Officer of Protega. “Our exclusive agreement regarding OPOS’ technological platform and service delivery helps physicians risk stratify patients through real-time monitoring and regulatory compliance, forming an integrated approach aimed at improving patient outcomes.”
Health Technology Insights: Roche to Invest $50Billion in US Pharmaceuticals and Diagnostics
Protega patented SentryBond technology, which is designed to prevent manipulation and misuse via nonoral routes of administration. Protega’s collaboration with OPOS further underscores the company’s position as a pharmaceutical and medtech company focused on deterring prescription medication misuse and abuse.
“It is critical to empower chronic pain patients to make informed care decisions. As such, we aim to improve long-term access to highly personalized care for appropriate patients through patient education combined with monitoring tools, supported by a framework of regulatory compliance,” said Justin Kromelow, Founder and Chief Executive Officer of OPOS. “The growing U.S. chronic pain patient population has been challenged with adequate access to care. Working with Protega, we are seeing results, already expanding to positively impact thousands of additional chronic pain patients and their providers.”
The growing need for pain management motivated Protega and OPOS to address the demand for effective, monitored treatment options for patients who experience functional benefit, while aiming to reduce the likelihood of misuse and abuse.
Research shows that chronic medical conditions are best managed not only by medication but in tandem with regular monitoring and lifestyle changes. Hence, providers need better end-to-end solutions that proactively and comprehensively monitor patient health, as well as encourage behavioral changes to improve adherence to prescribed medications, diet, and lifestyles.
Health Technology Insights: Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
